Quantum Surgical
- Industry
- Medical Robotics
- Founded Year
- 2017
- Headquarters
- Montpellier, France
- Employee Count
- 155
Key People
- Bertin Nahum - Co-founder & CEO
- Fernand Badano - Co-founder & General Manager
- Lucien Blondel - Co-founder & CTO
- Christophe Sibillin - Chief Financial Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced MedTech entrepreneurs with a proven track record.
The co-founders, including Bertin Nahum, have extensive experience in medical robotics and have successfully led previous ventures, such as Medtech S.A., which was acquired by Zimmer Biomet in 2016.
- Clinical Need
-
Aspect: Very Strong
Summary: The Epione platform addresses a significant unmet need in minimally invasive cancer treatment.
Epione offers a robotic-assisted solution for percutaneous ablation, providing an alternative to surgery for treating inoperable or challenging early-stage tumors, thereby addressing a critical gap in cancer care.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several players, but Quantum Surgical's unique approach differentiates it.
While the medical robotics field is competitive, Quantum Surgical's focus on minimally invasive cancer treatments and its innovative Epione platform provide a distinct value proposition.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and deploying advanced robotic systems for medical applications presents moderate technical challenges.
The integration of robotics and AI in medical procedures requires overcoming technical hurdles, but the company's experienced team is well-equipped to address these challenges.
- Patent
-
Aspect: Strong
Summary: Quantum Surgical holds strong patents protecting its innovative technologies.
The company's intellectual property portfolio provides a competitive edge and safeguards its technological innovations in the medical robotics space.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors.
With total funding of approximately $47 million from investors like Ally Bridge Group and Bpifrance, Quantum Surgical is well-positioned for growth and product development.
- Regulatory
-
Aspect: 510k/PMA
Summary: Epione has obtained CE marking and FDA clearance for specific indications.
The regulatory approvals for Epione in both Europe and the U.S. facilitate market entry and adoption, enhancing the company's credibility and market potential.
Opportunity Rollup
- Odds of Success
- 3.4
- Peak Market Share
- 4.3
- Segment CAGR
- 10.7%
- Market Segment
- Medical Robotics
- Market Sub Segment
- Oncology Treatment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
Quantum Surgical's innovative Epione platform positions the company to address a significant unmet need in minimally invasive cancer treatment, supported by a strong team and substantial funding.